nodes	percent_of_prediction	percent_of_DWPC	metapath
Ketamine—CYP2B6—Thiotepa—urinary bladder cancer	0.159	0.229	CbGbCtD
Ketamine—ABCB1—Mitomycin—urinary bladder cancer	0.107	0.155	CbGbCtD
Ketamine—PTGS1—Etoposide—urinary bladder cancer	0.0565	0.0814	CbGbCtD
Ketamine—CYP3A4—Thiotepa—urinary bladder cancer	0.0488	0.0703	CbGbCtD
Ketamine—CYP2B6—Cisplatin—urinary bladder cancer	0.0438	0.0631	CbGbCtD
Ketamine—CYP2C8—Fluorouracil—urinary bladder cancer	0.0391	0.0563	CbGbCtD
Ketamine—CYP2C8—Etoposide—urinary bladder cancer	0.0326	0.047	CbGbCtD
Ketamine—ABCB1—Gemcitabine—urinary bladder cancer	0.0309	0.0445	CbGbCtD
Ketamine—CYP2B6—Doxorubicin—urinary bladder cancer	0.0294	0.0423	CbGbCtD
Ketamine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0272	0.0393	CbGbCtD
Ketamine—CYP2C9—Cisplatin—urinary bladder cancer	0.0231	0.0333	CbGbCtD
Ketamine—ABCB1—Cisplatin—urinary bladder cancer	0.0225	0.0324	CbGbCtD
Ketamine—ABCB1—Etoposide—urinary bladder cancer	0.0221	0.0318	CbGbCtD
Ketamine—Clonus—Cisplatin—urinary bladder cancer	0.0162	0.114	CcSEcCtD
Ketamine—ABCB1—Doxorubicin—urinary bladder cancer	0.0151	0.0217	CbGbCtD
Ketamine—ABCB1—Methotrexate—urinary bladder cancer	0.0146	0.021	CbGbCtD
Ketamine—CYP3A4—Etoposide—urinary bladder cancer	0.0132	0.0191	CbGbCtD
Ketamine—CYP3A4—Doxorubicin—urinary bladder cancer	0.00902	0.013	CbGbCtD
Ketamine—Cystitis noninfective—Valrubicin—urinary bladder cancer	0.00672	0.0472	CcSEcCtD
Ketamine—Cystitis—Valrubicin—urinary bladder cancer	0.00664	0.0467	CcSEcCtD
Ketamine—Bladder pain—Valrubicin—urinary bladder cancer	0.00622	0.0437	CcSEcCtD
Ketamine—GRIN2D—prostate gland—urinary bladder cancer	0.00551	0.0997	CbGeAlD
Ketamine—Obstructive airways disorder—Methotrexate—urinary bladder cancer	0.00451	0.0317	CcSEcCtD
Ketamine—TACR1—prostate gland—urinary bladder cancer	0.00449	0.0812	CbGeAlD
Ketamine—CYP2C9—urine—urinary bladder cancer	0.00371	0.067	CbGeAlD
Ketamine—OPRK1—prostate gland—urinary bladder cancer	0.0035	0.0633	CbGeAlD
Ketamine—TACR1—smooth muscle tissue—urinary bladder cancer	0.00318	0.0575	CbGeAlD
Ketamine—TACR1—renal system—urinary bladder cancer	0.00306	0.0554	CbGeAlD
Ketamine—CYP3A4—urine—urinary bladder cancer	0.00283	0.0511	CbGeAlD
Ketamine—Nystagmus—Fluorouracil—urinary bladder cancer	0.00276	0.0194	CcSEcCtD
Ketamine—OPRD1—renal system—urinary bladder cancer	0.00249	0.045	CbGeAlD
Ketamine—TACR1—female reproductive system—urinary bladder cancer	0.00245	0.0443	CbGeAlD
Ketamine—Cystitis noninfective—Thiotepa—urinary bladder cancer	0.00233	0.0164	CcSEcCtD
Ketamine—Cystitis—Thiotepa—urinary bladder cancer	0.0023	0.0162	CcSEcCtD
Ketamine—Laryngospasm—Etoposide—urinary bladder cancer	0.00229	0.0161	CcSEcCtD
Ketamine—Bladder pain—Thiotepa—urinary bladder cancer	0.00215	0.0151	CcSEcCtD
Ketamine—Erythema—Mitomycin—urinary bladder cancer	0.00207	0.0146	CcSEcCtD
Ketamine—GRIN2A—vagina—urinary bladder cancer	0.00202	0.0366	CbGeAlD
Ketamine—Apnoea—Etoposide—urinary bladder cancer	0.00202	0.0142	CcSEcCtD
Ketamine—Vision blurred—Mitomycin—urinary bladder cancer	0.00195	0.0137	CcSEcCtD
Ketamine—Pain—Carboplatin—urinary bladder cancer	0.00194	0.0137	CcSEcCtD
Ketamine—OPRK1—female reproductive system—urinary bladder cancer	0.00191	0.0346	CbGeAlD
Ketamine—Shock—Mitomycin—urinary bladder cancer	0.00166	0.0117	CcSEcCtD
Ketamine—Anorexia—Mitomycin—urinary bladder cancer	0.00161	0.0113	CcSEcCtD
Ketamine—Vomiting—Valrubicin—urinary bladder cancer	0.00156	0.011	CcSEcCtD
Ketamine—Rash—Valrubicin—urinary bladder cancer	0.00155	0.0109	CcSEcCtD
Ketamine—Dermatitis—Valrubicin—urinary bladder cancer	0.00155	0.0109	CcSEcCtD
Ketamine—Decreased appetite—Mitomycin—urinary bladder cancer	0.00147	0.0103	CcSEcCtD
Ketamine—Nausea—Valrubicin—urinary bladder cancer	0.00146	0.0102	CcSEcCtD
Ketamine—Pain—Mitomycin—urinary bladder cancer	0.00145	0.0102	CcSEcCtD
Ketamine—TACR1—lymph node—urinary bladder cancer	0.00144	0.0259	CbGeAlD
Ketamine—Nystagmus—Epirubicin—urinary bladder cancer	0.00134	0.00944	CcSEcCtD
Ketamine—Nystagmus—Doxorubicin—urinary bladder cancer	0.00124	0.00873	CcSEcCtD
Ketamine—PTGS1—prostate gland—urinary bladder cancer	0.00121	0.022	CbGeAlD
Ketamine—Apnoea—Methotrexate—urinary bladder cancer	0.00121	0.0085	CcSEcCtD
Ketamine—Vomiting—Mitomycin—urinary bladder cancer	0.00107	0.00755	CcSEcCtD
Ketamine—Arrhythmia—Thiotepa—urinary bladder cancer	0.00107	0.00751	CcSEcCtD
Ketamine—Rash—Mitomycin—urinary bladder cancer	0.00107	0.00749	CcSEcCtD
Ketamine—Dermatitis—Mitomycin—urinary bladder cancer	0.00106	0.00748	CcSEcCtD
Ketamine—Erythema—Thiotepa—urinary bladder cancer	0.00104	0.00732	CcSEcCtD
Ketamine—PTGS1—seminal vesicle—urinary bladder cancer	0.00103	0.0186	CbGeAlD
Ketamine—CYP2C8—renal system—urinary bladder cancer	0.00102	0.0185	CbGeAlD
Ketamine—Nausea—Mitomycin—urinary bladder cancer	0.001	0.00706	CcSEcCtD
Ketamine—Cystitis noninfective—Methotrexate—urinary bladder cancer	0.001	0.00704	CcSEcCtD
Ketamine—SLC6A2—female reproductive system—urinary bladder cancer	0.000995	0.018	CbGeAlD
Ketamine—Cystitis—Methotrexate—urinary bladder cancer	0.00099	0.00696	CcSEcCtD
Ketamine—Vision blurred—Thiotepa—urinary bladder cancer	0.000981	0.0069	CcSEcCtD
Ketamine—Bradycardia—Cisplatin—urinary bladder cancer	0.000955	0.00671	CcSEcCtD
Ketamine—Cystitis noninfective—Epirubicin—urinary bladder cancer	0.000937	0.00659	CcSEcCtD
Ketamine—Salivary hypersecretion—Epirubicin—urinary bladder cancer	0.000931	0.00655	CcSEcCtD
Ketamine—Bladder pain—Methotrexate—urinary bladder cancer	0.000927	0.00651	CcSEcCtD
Ketamine—Cystitis—Epirubicin—urinary bladder cancer	0.000926	0.00651	CcSEcCtD
Ketamine—CYP2B6—renal system—urinary bladder cancer	0.000916	0.0166	CbGeAlD
Ketamine—Convulsion—Thiotepa—urinary bladder cancer	0.000902	0.00634	CcSEcCtD
Ketamine—Arrhythmia—Gemcitabine—urinary bladder cancer	0.000899	0.00632	CcSEcCtD
Ketamine—PTGS1—epithelium—urinary bladder cancer	0.000893	0.0161	CbGeAlD
Ketamine—Arrhythmia—Fluorouracil—urinary bladder cancer	0.000884	0.00621	CcSEcCtD
Ketamine—Erythema—Gemcitabine—urinary bladder cancer	0.000876	0.00616	CcSEcCtD
Ketamine—Bladder pain—Epirubicin—urinary bladder cancer	0.000867	0.0061	CcSEcCtD
Ketamine—Cystitis noninfective—Doxorubicin—urinary bladder cancer	0.000867	0.00609	CcSEcCtD
Ketamine—Salivary hypersecretion—Doxorubicin—urinary bladder cancer	0.000862	0.00606	CcSEcCtD
Ketamine—Erythema—Fluorouracil—urinary bladder cancer	0.000861	0.00605	CcSEcCtD
Ketamine—PTGS1—smooth muscle tissue—urinary bladder cancer	0.00086	0.0156	CbGeAlD
Ketamine—Cystitis—Doxorubicin—urinary bladder cancer	0.000857	0.00602	CcSEcCtD
Ketamine—Arrhythmia—Cisplatin—urinary bladder cancer	0.000838	0.00589	CcSEcCtD
Ketamine—PTGS1—renal system—urinary bladder cancer	0.000828	0.015	CbGeAlD
Ketamine—CYP2C8—female reproductive system—urinary bladder cancer	0.000818	0.0148	CbGeAlD
Ketamine—Erythema—Cisplatin—urinary bladder cancer	0.000816	0.00574	CcSEcCtD
Ketamine—Vision blurred—Fluorouracil—urinary bladder cancer	0.000812	0.00571	CcSEcCtD
Ketamine—Anorexia—Thiotepa—urinary bladder cancer	0.00081	0.00569	CcSEcCtD
Ketamine—Bladder pain—Doxorubicin—urinary bladder cancer	0.000802	0.00564	CcSEcCtD
Ketamine—Vision blurred—Cisplatin—urinary bladder cancer	0.000769	0.00541	CcSEcCtD
Ketamine—Convulsion—Fluorouracil—urinary bladder cancer	0.000746	0.00525	CcSEcCtD
Ketamine—CYP2C8—vagina—urinary bladder cancer	0.00074	0.0134	CbGeAlD
Ketamine—Decreased appetite—Thiotepa—urinary bladder cancer	0.000739	0.00519	CcSEcCtD
Ketamine—CYP2B6—female reproductive system—urinary bladder cancer	0.000734	0.0133	CbGeAlD
Ketamine—Pain—Thiotepa—urinary bladder cancer	0.000727	0.00511	CcSEcCtD
Ketamine—CYP2C9—female reproductive system—urinary bladder cancer	0.000726	0.0131	CbGeAlD
Ketamine—ABCB1—prostate gland—urinary bladder cancer	0.000718	0.013	CbGeAlD
Ketamine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000715	0.00503	CcSEcCtD
Ketamine—Convulsion—Cisplatin—urinary bladder cancer	0.000707	0.00497	CcSEcCtD
Ketamine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000703	0.00494	CcSEcCtD
Ketamine—Diplopia—Epirubicin—urinary bladder cancer	0.000696	0.00489	CcSEcCtD
Ketamine—CYP3A4—renal system—urinary bladder cancer	0.000692	0.0125	CbGeAlD
Ketamine—Anorexia—Gemcitabine—urinary bladder cancer	0.000681	0.00479	CcSEcCtD
Ketamine—Anorexia—Fluorouracil—urinary bladder cancer	0.00067	0.00471	CcSEcCtD
Ketamine—Hypotension—Gemcitabine—urinary bladder cancer	0.000668	0.0047	CcSEcCtD
Ketamine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000666	0.00468	CcSEcCtD
Ketamine—CYP2B6—vagina—urinary bladder cancer	0.000663	0.012	CbGeAlD
Ketamine—PTGS1—female reproductive system—urinary bladder cancer	0.000663	0.012	CbGeAlD
Ketamine—Hypotension—Fluorouracil—urinary bladder cancer	0.000657	0.00462	CcSEcCtD
Ketamine—Convulsion—Etoposide—urinary bladder cancer	0.000648	0.00456	CcSEcCtD
Ketamine—Diplopia—Doxorubicin—urinary bladder cancer	0.000644	0.00453	CcSEcCtD
Ketamine—Anorexia—Cisplatin—urinary bladder cancer	0.000635	0.00446	CcSEcCtD
Ketamine—Hypotension—Cisplatin—urinary bladder cancer	0.000623	0.00438	CcSEcCtD
Ketamine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000621	0.00437	CcSEcCtD
Ketamine—Pain—Gemcitabine—urinary bladder cancer	0.000611	0.0043	CcSEcCtD
Ketamine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000611	0.0043	CcSEcCtD
Ketamine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00061	0.00429	CcSEcCtD
Ketamine—ABCB1—seminal vesicle—urinary bladder cancer	0.000608	0.011	CbGeAlD
Ketamine—Pain—Fluorouracil—urinary bladder cancer	0.000601	0.00423	CcSEcCtD
Ketamine—PTGS1—vagina—urinary bladder cancer	0.0006	0.0108	CbGeAlD
Ketamine—SLC6A2—lymph node—urinary bladder cancer	0.000582	0.0105	CbGeAlD
Ketamine—Anorexia—Etoposide—urinary bladder cancer	0.000582	0.00409	CcSEcCtD
Ketamine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000579	0.00407	CcSEcCtD
Ketamine—Hypotension—Etoposide—urinary bladder cancer	0.00057	0.00401	CcSEcCtD
Ketamine—Pain—Cisplatin—urinary bladder cancer	0.00057	0.00401	CcSEcCtD
Ketamine—CYP3A4—female reproductive system—urinary bladder cancer	0.000554	0.01	CbGeAlD
Ketamine—Vomiting—Thiotepa—urinary bladder cancer	0.00054	0.0038	CcSEcCtD
Ketamine—Rash—Thiotepa—urinary bladder cancer	0.000536	0.00377	CcSEcCtD
Ketamine—Dermatitis—Thiotepa—urinary bladder cancer	0.000535	0.00376	CcSEcCtD
Ketamine—Decreased appetite—Etoposide—urinary bladder cancer	0.000531	0.00373	CcSEcCtD
Ketamine—ABCB1—epithelium—urinary bladder cancer	0.000528	0.00954	CbGeAlD
Ketamine—Pain—Etoposide—urinary bladder cancer	0.000522	0.00367	CcSEcCtD
Ketamine—Nausea—Thiotepa—urinary bladder cancer	0.000505	0.00355	CcSEcCtD
Ketamine—Bradycardia—Epirubicin—urinary bladder cancer	0.00049	0.00345	CcSEcCtD
Ketamine—ABCB1—renal system—urinary bladder cancer	0.00049	0.00885	CbGeAlD
Ketamine—ABCB1—urethra—urinary bladder cancer	0.000481	0.00869	CbGeAlD
Ketamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000455	0.0032	CcSEcCtD
Ketamine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000454	0.00319	CcSEcCtD
Ketamine—Rash—Gemcitabine—urinary bladder cancer	0.000451	0.00317	CcSEcCtD
Ketamine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00045	0.00317	CcSEcCtD
Ketamine—Erythema—Methotrexate—urinary bladder cancer	0.000448	0.00315	CcSEcCtD
Ketamine—Vomiting—Fluorouracil—urinary bladder cancer	0.000447	0.00314	CcSEcCtD
Ketamine—Rash—Fluorouracil—urinary bladder cancer	0.000443	0.00312	CcSEcCtD
Ketamine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000443	0.00311	CcSEcCtD
Ketamine—Arrhythmia—Epirubicin—urinary bladder cancer	0.00043	0.00302	CcSEcCtD
Ketamine—Nausea—Gemcitabine—urinary bladder cancer	0.000425	0.00298	CcSEcCtD
Ketamine—Vomiting—Cisplatin—urinary bladder cancer	0.000424	0.00298	CcSEcCtD
Ketamine—Vision blurred—Methotrexate—urinary bladder cancer	0.000422	0.00297	CcSEcCtD
Ketamine—Rash—Cisplatin—urinary bladder cancer	0.00042	0.00295	CcSEcCtD
Ketamine—Dermatitis—Cisplatin—urinary bladder cancer	0.00042	0.00295	CcSEcCtD
Ketamine—Erythema—Epirubicin—urinary bladder cancer	0.000419	0.00295	CcSEcCtD
Ketamine—Nausea—Fluorouracil—urinary bladder cancer	0.000418	0.00293	CcSEcCtD
Ketamine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000398	0.0028	CcSEcCtD
Ketamine—Nausea—Cisplatin—urinary bladder cancer	0.000396	0.00278	CcSEcCtD
Ketamine—Vision blurred—Epirubicin—urinary bladder cancer	0.000395	0.00278	CcSEcCtD
Ketamine—ABCB1—female reproductive system—urinary bladder cancer	0.000392	0.00709	CbGeAlD
Ketamine—Convulsion—Methotrexate—urinary bladder cancer	0.000388	0.00273	CcSEcCtD
Ketamine—Vomiting—Etoposide—urinary bladder cancer	0.000388	0.00273	CcSEcCtD
Ketamine—Erythema—Doxorubicin—urinary bladder cancer	0.000388	0.00273	CcSEcCtD
Ketamine—PTGS1—lymph node—urinary bladder cancer	0.000388	0.00701	CbGeAlD
Ketamine—Rash—Etoposide—urinary bladder cancer	0.000385	0.00271	CcSEcCtD
Ketamine—Dermatitis—Etoposide—urinary bladder cancer	0.000385	0.0027	CcSEcCtD
Ketamine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000366	0.00257	CcSEcCtD
Ketamine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000366	0.00257	CcSEcCtD
Ketamine—Convulsion—Epirubicin—urinary bladder cancer	0.000363	0.00255	CcSEcCtD
Ketamine—Nausea—Etoposide—urinary bladder cancer	0.000363	0.00255	CcSEcCtD
Ketamine—ABCB1—vagina—urinary bladder cancer	0.000355	0.00641	CbGeAlD
Ketamine—Anorexia—Methotrexate—urinary bladder cancer	0.000349	0.00245	CcSEcCtD
Ketamine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000342	0.00241	CcSEcCtD
Ketamine—Hypotension—Methotrexate—urinary bladder cancer	0.000342	0.0024	CcSEcCtD
Ketamine—Shock—Epirubicin—urinary bladder cancer	0.000337	0.00237	CcSEcCtD
Ketamine—Convulsion—Doxorubicin—urinary bladder cancer	0.000336	0.00236	CcSEcCtD
Ketamine—Anorexia—Epirubicin—urinary bladder cancer	0.000326	0.00229	CcSEcCtD
Ketamine—Hypotension—Epirubicin—urinary bladder cancer	0.00032	0.00225	CcSEcCtD
Ketamine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000318	0.00223	CcSEcCtD
Ketamine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000317	0.00223	CcSEcCtD
Ketamine—Pain—Methotrexate—urinary bladder cancer	0.000313	0.0022	CcSEcCtD
Ketamine—Shock—Doxorubicin—urinary bladder cancer	0.000311	0.00219	CcSEcCtD
Ketamine—Anorexia—Doxorubicin—urinary bladder cancer	0.000302	0.00212	CcSEcCtD
Ketamine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000297	0.00209	CcSEcCtD
Ketamine—Hypotension—Doxorubicin—urinary bladder cancer	0.000296	0.00208	CcSEcCtD
Ketamine—Pain—Epirubicin—urinary bladder cancer	0.000293	0.00206	CcSEcCtD
Ketamine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000275	0.00193	CcSEcCtD
Ketamine—Pain—Doxorubicin—urinary bladder cancer	0.000271	0.0019	CcSEcCtD
Ketamine—Vomiting—Methotrexate—urinary bladder cancer	0.000232	0.00163	CcSEcCtD
Ketamine—Rash—Methotrexate—urinary bladder cancer	0.000231	0.00162	CcSEcCtD
Ketamine—Dermatitis—Methotrexate—urinary bladder cancer	0.00023	0.00162	CcSEcCtD
Ketamine—ABCB1—lymph node—urinary bladder cancer	0.000229	0.00415	CbGeAlD
Ketamine—Vomiting—Epirubicin—urinary bladder cancer	0.000218	0.00153	CcSEcCtD
Ketamine—Nausea—Methotrexate—urinary bladder cancer	0.000217	0.00153	CcSEcCtD
Ketamine—Rash—Epirubicin—urinary bladder cancer	0.000216	0.00152	CcSEcCtD
Ketamine—Dermatitis—Epirubicin—urinary bladder cancer	0.000216	0.00152	CcSEcCtD
Ketamine—Nausea—Epirubicin—urinary bladder cancer	0.000203	0.00143	CcSEcCtD
Ketamine—Vomiting—Doxorubicin—urinary bladder cancer	0.000201	0.00142	CcSEcCtD
Ketamine—Rash—Doxorubicin—urinary bladder cancer	0.0002	0.0014	CcSEcCtD
Ketamine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000199	0.0014	CcSEcCtD
Ketamine—Nausea—Doxorubicin—urinary bladder cancer	0.000188	0.00132	CcSEcCtD
Ketamine—TACR1—Signaling Pathways—CCND1—urinary bladder cancer	2.67e-05	0.000246	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.64e-05	0.000243	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.64e-05	0.000243	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—GSTT1—urinary bladder cancer	2.61e-05	0.000241	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—IL2—urinary bladder cancer	2.61e-05	0.00024	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—TERT—urinary bladder cancer	2.6e-05	0.00024	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—MMP9—urinary bladder cancer	2.59e-05	0.000239	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—NCOR1—urinary bladder cancer	2.59e-05	0.000238	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—CDKN1A—urinary bladder cancer	2.58e-05	0.000238	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—PTEN—urinary bladder cancer	2.57e-05	0.000237	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.57e-05	0.000237	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.56e-05	0.000236	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.55e-05	0.000235	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—RBX1—urinary bladder cancer	2.54e-05	0.000234	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	2.54e-05	0.000234	CbGpPWpGaD
Ketamine—OPRK1—GPCR downstream signaling—IL2—urinary bladder cancer	2.52e-05	0.000232	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.51e-05	0.000231	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.49e-05	0.000229	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.48e-05	0.000229	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.46e-05	0.000227	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—RRM2—urinary bladder cancer	2.46e-05	0.000227	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—EP300—urinary bladder cancer	2.46e-05	0.000226	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—S100B—urinary bladder cancer	2.43e-05	0.000224	CbGpPWpGaD
Ketamine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.41e-05	0.000222	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—CXCL8—urinary bladder cancer	2.39e-05	0.000221	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—TSC1—urinary bladder cancer	2.39e-05	0.00022	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—SRC—urinary bladder cancer	2.39e-05	0.00022	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—FGFR3—urinary bladder cancer	2.39e-05	0.00022	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—GSTP1—urinary bladder cancer	2.37e-05	0.000219	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.32e-05	0.000214	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—ESR1—urinary bladder cancer	2.32e-05	0.000214	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—RHOA—urinary bladder cancer	2.3e-05	0.000212	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.3e-05	0.000212	CbGpPWpGaD
Ketamine—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.29e-05	0.000211	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—IL2—urinary bladder cancer	2.29e-05	0.000211	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—TERT—urinary bladder cancer	2.28e-05	0.00021	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—ENO2—urinary bladder cancer	2.28e-05	0.00021	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	2.28e-05	0.00021	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—JAG1—urinary bladder cancer	2.28e-05	0.00021	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.27e-05	0.000209	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	2.23e-05	0.000205	CbGpPWpGaD
Ketamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.21e-05	0.000204	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	2.21e-05	0.000204	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—TYMS—urinary bladder cancer	2.2e-05	0.000203	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—NCOR1—urinary bladder cancer	2.19e-05	0.000201	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—NCOR1—urinary bladder cancer	2.18e-05	0.000201	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—GSTM1—urinary bladder cancer	2.18e-05	0.000201	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.18e-05	0.000201	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.17e-05	0.0002	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—NQO1—urinary bladder cancer	2.17e-05	0.0002	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.14e-05	0.000198	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—MYC—urinary bladder cancer	2.14e-05	0.000197	CbGpPWpGaD
Ketamine—OPRM1—GPCR downstream signaling—IL2—urinary bladder cancer	2.13e-05	0.000196	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.12e-05	0.000195	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—EGFR—urinary bladder cancer	2.09e-05	0.000193	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—FGFR3—urinary bladder cancer	2.09e-05	0.000193	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—GPX1—urinary bladder cancer	2.09e-05	0.000192	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—ERCC2—urinary bladder cancer	2.05e-05	0.000189	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—ESR1—urinary bladder cancer	2.03e-05	0.000187	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CREBBP—urinary bladder cancer	2.03e-05	0.000187	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	2.02e-05	0.000186	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—IGF1—urinary bladder cancer	2.01e-05	0.000185	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2e-05	0.000185	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—EGFR—urinary bladder cancer	2e-05	0.000184	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.98e-05	0.000183	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.98e-05	0.000183	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—KRAS—urinary bladder cancer	1.98e-05	0.000182	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—IL2—urinary bladder cancer	1.93e-05	0.000178	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—TERT—urinary bladder cancer	1.93e-05	0.000178	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—MTHFR—urinary bladder cancer	1.93e-05	0.000178	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.93e-05	0.000177	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—RHOA—urinary bladder cancer	1.92e-05	0.000177	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—KRAS—urinary bladder cancer	1.88e-05	0.000174	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.85e-05	0.000171	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.85e-05	0.000171	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.84e-05	0.00017	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—S100B—urinary bladder cancer	1.84e-05	0.00017	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—RHOA—urinary bladder cancer	1.84e-05	0.000169	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.84e-05	0.000169	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	1.81e-05	0.000167	CbGpPWpGaD
Ketamine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.8e-05	0.000166	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.8e-05	0.000166	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.78e-05	0.000164	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CREBBP—urinary bladder cancer	1.78e-05	0.000164	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.77e-05	0.000163	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—FGFR3—urinary bladder cancer	1.77e-05	0.000163	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—IGF1—urinary bladder cancer	1.76e-05	0.000162	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—TP53—urinary bladder cancer	1.76e-05	0.000162	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—EGFR—urinary bladder cancer	1.75e-05	0.000161	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—RHOA—urinary bladder cancer	1.75e-05	0.000161	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—ESR1—urinary bladder cancer	1.72e-05	0.000158	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—ERBB2—urinary bladder cancer	1.7e-05	0.000157	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.69e-05	0.000156	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.69e-05	0.000156	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—TYMS—urinary bladder cancer	1.68e-05	0.000155	CbGpPWpGaD
Ketamine—TACR1—Signaling Pathways—HRAS—urinary bladder cancer	1.68e-05	0.000155	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	1.66e-05	0.000153	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	1.66e-05	0.000153	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—NCOR1—urinary bladder cancer	1.66e-05	0.000153	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—KRAS—urinary bladder cancer	1.65e-05	0.000152	CbGpPWpGaD
Ketamine—DRD2—GPCR downstream signaling—IL2—urinary bladder cancer	1.61e-05	0.000149	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CXCL8—urinary bladder cancer	1.61e-05	0.000149	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—RHOA—urinary bladder cancer	1.61e-05	0.000148	CbGpPWpGaD
Ketamine—OPRD1—Signaling by GPCR—HRAS—urinary bladder cancer	1.6e-05	0.000148	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.6e-05	0.000147	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—GPX1—urinary bladder cancer	1.59e-05	0.000147	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	1.56e-05	0.000144	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PPARG—urinary bladder cancer	1.56e-05	0.000144	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.55e-05	0.000143	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—IL2—urinary bladder cancer	1.54e-05	0.000142	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—CXCL8—urinary bladder cancer	1.53e-05	0.000141	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.53e-05	0.000141	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.53e-05	0.000141	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CREBBP—urinary bladder cancer	1.5e-05	0.000139	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CCND1—urinary bladder cancer	1.5e-05	0.000138	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—CREBBP—urinary bladder cancer	1.5e-05	0.000138	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.49e-05	0.000138	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—ERBB2—urinary bladder cancer	1.49e-05	0.000137	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—IGF1—urinary bladder cancer	1.49e-05	0.000137	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.48e-05	0.000137	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—EGFR—urinary bladder cancer	1.48e-05	0.000136	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	1.47e-05	0.000135	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—IL2—urinary bladder cancer	1.47e-05	0.000135	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—TERT—urinary bladder cancer	1.46e-05	0.000135	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—MMP9—urinary bladder cancer	1.46e-05	0.000134	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.45e-05	0.000134	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.45e-05	0.000134	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—PTEN—urinary bladder cancer	1.45e-05	0.000134	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.42e-05	0.000131	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CXCL8—urinary bladder cancer	1.41e-05	0.00013	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.41e-05	0.00013	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.41e-05	0.00013	CbGpPWpGaD
Ketamine—OPRK1—Signaling by GPCR—HRAS—urinary bladder cancer	1.4e-05	0.00013	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—KRAS—urinary bladder cancer	1.4e-05	0.000129	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—EP300—urinary bladder cancer	1.38e-05	0.000127	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—RHOA—urinary bladder cancer	1.36e-05	0.000125	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—IL2—urinary bladder cancer	1.35e-05	0.000125	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.35e-05	0.000124	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—SRC—urinary bladder cancer	1.34e-05	0.000124	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—FGFR3—urinary bladder cancer	1.34e-05	0.000124	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.33e-05	0.000123	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.32e-05	0.000122	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.32e-05	0.000122	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CCND1—urinary bladder cancer	1.32e-05	0.000121	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—ESR1—urinary bladder cancer	1.3e-05	0.00012	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—MMP9—urinary bladder cancer	1.28e-05	0.000118	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.27e-05	0.000117	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—PTEN—urinary bladder cancer	1.27e-05	0.000117	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.26e-05	0.000117	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—ERBB2—urinary bladder cancer	1.26e-05	0.000116	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.25e-05	0.000115	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.24e-05	0.000115	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.24e-05	0.000114	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PTGS2—urinary bladder cancer	1.23e-05	0.000113	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.23e-05	0.000113	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.23e-05	0.000113	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.22e-05	0.000113	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.22e-05	0.000113	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—EP300—urinary bladder cancer	1.21e-05	0.000112	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.21e-05	0.000111	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—MYC—urinary bladder cancer	1.21e-05	0.000111	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CXCL8—urinary bladder cancer	1.2e-05	0.00011	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PPARG—urinary bladder cancer	1.19e-05	0.00011	CbGpPWpGaD
Ketamine—OPRM1—Signaling by GPCR—HRAS—urinary bladder cancer	1.19e-05	0.000109	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.19e-05	0.000109	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—SRC—urinary bladder cancer	1.18e-05	0.000109	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.18e-05	0.000109	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.17e-05	0.000108	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.16e-05	0.000107	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.15e-05	0.000106	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.15e-05	0.000106	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.15e-05	0.000106	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	1.14e-05	0.000106	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—IL2—urinary bladder cancer	1.14e-05	0.000105	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	1.14e-05	0.000105	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	1.13e-05	0.000104	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	1.12e-05	0.000103	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.11e-05	0.000103	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CCND1—urinary bladder cancer	1.11e-05	0.000103	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.1e-05	0.000101	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.08e-05	9.99e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—MMP9—urinary bladder cancer	1.08e-05	9.96e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	9.93e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.08e-05	9.93e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—PTEN—urinary bladder cancer	1.07e-05	9.91e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—PTEN—urinary bladder cancer	1.07e-05	9.88e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	1.06e-05	9.76e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—MYC—urinary bladder cancer	1.06e-05	9.74e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—EGFR—urinary bladder cancer	1.03e-05	9.53e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	1.03e-05	9.51e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—EP300—urinary bladder cancer	1.02e-05	9.45e-05	CbGpPWpGaD
Ketamine—PTGS1—Metabolism—EP300—urinary bladder cancer	1.02e-05	9.42e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.01e-05	9.33e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.01e-05	9.3e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—SRC—urinary bladder cancer	9.97e-06	9.19e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—TP53—urinary bladder cancer	9.9e-06	9.12e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.86e-06	9.09e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—KRAS—urinary bladder cancer	9.76e-06	9e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	9.69e-06	8.93e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	9.55e-06	8.8e-05	CbGpPWpGaD
Ketamine—OPRD1—Signaling Pathways—HRAS—urinary bladder cancer	9.46e-06	8.72e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	9.37e-06	8.64e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	9.06e-06	8.35e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	9e-06	8.3e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—MYC—urinary bladder cancer	8.93e-06	8.23e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.79e-06	8.1e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—EGFR—urinary bladder cancer	8.73e-06	8.05e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—TP53—urinary bladder cancer	8.68e-06	8e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	8.66e-06	7.98e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	8.44e-06	7.78e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	8.44e-06	7.78e-05	CbGpPWpGaD
Ketamine—OPRK1—Signaling Pathways—HRAS—urinary bladder cancer	8.3e-06	7.65e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—KRAS—urinary bladder cancer	8.25e-06	7.61e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.22e-06	7.58e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	8.21e-06	7.57e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	8.19e-06	7.55e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—PTEN—urinary bladder cancer	8.17e-06	7.54e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	8.16e-06	7.52e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	8.14e-06	7.51e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	7.94e-06	7.32e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	7.89e-06	7.27e-05	CbGpPWpGaD
Ketamine—CYP2B6—Metabolism—EP300—urinary bladder cancer	7.8e-06	7.19e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	7.77e-06	7.16e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.64e-06	7.05e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.56e-06	6.96e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.56e-06	6.96e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	7.55e-06	6.96e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—TP53—urinary bladder cancer	7.33e-06	6.76e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.24e-06	6.67e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.1e-06	6.55e-05	CbGpPWpGaD
Ketamine—OPRM1—Signaling Pathways—HRAS—urinary bladder cancer	7.01e-06	6.47e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	6.92e-06	6.38e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.91e-06	6.37e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	6.77e-06	6.24e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.68e-06	6.16e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	6.62e-06	6.1e-05	CbGpPWpGaD
Ketamine—CYP2C8—Metabolism—EP300—urinary bladder cancer	6.6e-06	6.08e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	6.46e-06	5.95e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	6.25e-06	5.76e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—PTEN—urinary bladder cancer	6.03e-06	5.56e-05	CbGpPWpGaD
Ketamine—ABCB1—Metabolism—EP300—urinary bladder cancer	5.75e-06	5.3e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	5.63e-06	5.19e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	5.56e-06	5.12e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.41e-06	4.99e-05	CbGpPWpGaD
Ketamine—CYP2C9—Metabolism—EP300—urinary bladder cancer	5.37e-06	4.95e-05	CbGpPWpGaD
Ketamine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	5.32e-06	4.9e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.2e-06	4.79e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.26e-06	3.93e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.71e-06	3.42e-05	CbGpPWpGaD
Ketamine—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.54e-06	3.27e-05	CbGpPWpGaD
